Literature DB >> 17939757

Detection of high- and low-affinity antibodies against a human monoclonal antibody using various technology platforms.

Meina Liang1, Scott L Klakamp, Cherryl Funelas, Hong Lu, Brandon Lam, Carina Herl, Amber Umble, Andrew W Drake, Min Pak, Natasha Ageyeva, Rao Pasumarthi, Lorin K Roskos.   

Abstract

The effect of monoclonal antibody (mAb) affinity on the detection limit of enzyme-linked immunosorbent assay (ELISA), surface plasmon resonance (SPR), and electrochemiluminescence (ECL) methods was evaluated using a panel of murine mAbs with affinities ranging from 0.057 to 340 nM. M1 and M7 are anti-idiotypic mAbs against a human mAb, ABX10, with dissociation equilibrium constant (KD) values of 0.057 and 7.2 nM, respectively. HP6030 and HP6002 are anti human IgG mAbs with KD values of 30 and 340 nM, respectively. The limit of detection (LOD) for these mAbs was determined using ELISA, SPR, and ECL technologies and was generally correlated with the rank order of their affinities. The LODs for M1, M7, HP6030, and HP6002 by ELISA were 17 +/- 13, 26,000 +/- 9,020, 344,000 +/- 271,000, and 792,000 +/- 1,050,000 ng/ml, respectively. According to an industry-suggested detection limit of 500 ng/ml, the ELISA was not sensitive enough for detecting M7, HP6030, and HP6002, demonstrating its limitation for detection of low- affinity mAbs. The SPR method lowered the LOD for M7 to 3,900 ng/ml, which was above the industry requirement. The ECL method lowered the LOD for all antibodies tested. Importantly, the ECL method lowered the LOD for M7 to 570 +/- 370 ng/ml, which is close to the industry requirement. Since the ECL method had demonstrated a high serum tolerance, its detection capability may be improved by using a higher percentage of serum in the assay matrix. Although a hook effect was observed with ECL methods, the methods could still detect anti-drug antibody (ADA) concentrations greater than 1 mg/ml, which minimizes concerns that high-titer ADA responses could be missed. The results demonstrated the superiority of an ECL method in detecting high- and low- affinity antibodies when compared to the ELISA and SPR methods.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17939757     DOI: 10.1089/adt.2007.089

Source DB:  PubMed          Journal:  Assay Drug Dev Technol        ISSN: 1540-658X            Impact factor:   1.738


  17 in total

1.  Oligoclonal antibody targeting ghrelin increases energy expenditure and reduces food intake in fasted mice.

Authors:  Joseph S Zakhari; Eric P Zorrilla; Bin Zhou; Alexander V Mayorov; Kim D Janda
Journal:  Mol Pharm       Date:  2011-12-23       Impact factor: 4.939

Review 2.  Immunogenicity to therapeutic proteins: impact on PK/PD and efficacy.

Authors:  Narendra Chirmule; Vibha Jawa; Bernd Meibohm
Journal:  AAPS J       Date:  2012-03-10       Impact factor: 4.009

3.  Ligand binding assays in the 21st Century laboratory: platforms.

Authors:  Franklin P Spriggs; Zhandong Don Zhong; Afshin Safavi; Darshana Jani; Narasaiah Dontha; Anita Kant; Jenny Ly; Lia Brilando; Karolina Österlund; Nathalie Rouleau; Saloumeh Kadkhodayan Fischer; Martin Boissonneault; Chad Ray
Journal:  AAPS J       Date:  2012-03       Impact factor: 4.009

Review 4.  Application of quantitative pharmacology in development of therapeutic monoclonal antibodies.

Authors:  Mohammad Tabrizi; Cherryl Funelas; Hamza Suria
Journal:  AAPS J       Date:  2010-07-24       Impact factor: 4.009

Review 5.  Antidrug antibody assay validation: industry survey results.

Authors:  Boris Gorovits
Journal:  AAPS J       Date:  2009-03-03       Impact factor: 4.009

6.  Establishment of reverse direct ELISA and its application in screening high-affinity monoclonal antibodies.

Authors:  Chunmei Zhang; Rende Li; Yongming Li; Chaojun Song; Zhijia Liu; Yun Zhang; Zhuwei Xu; Ran Zhuang; Jing Yi; Angang Yang; Kun Yang; Boquan Jin
Journal:  Hybridoma (Larchmt)       Date:  2012-08

7.  Anti-drug Antibody Assay Validation: Improved Reporting of the Assay Selectivity via Simpler Positive Control Recovery Data Analysis.

Authors:  Boris Gorovits; Marcela Araya Roldan; Daniel Baltrukonis; Chun-Hua Cai; Jean Donley; Darshana Jani; John Kamerud; Frederick McCush; Jeffrey S Thomas; Ying Wang
Journal:  AAPS J       Date:  2019-06-18       Impact factor: 4.009

8.  Anti-drug Antibody Assay Conditions Significantly Impact Assay Screen and Confirmatory Cut-Points.

Authors:  Boris Gorovits; Ying Wang; Liang Zhu; Marcela Araya; John Kamerud; Christopher Lepsy
Journal:  AAPS J       Date:  2019-06-03       Impact factor: 4.009

Review 9.  Immunogenicity of biologic agents in rheumatology.

Authors:  Vibeke Strand; Joao Goncalves; John D Isaacs
Journal:  Nat Rev Rheumatol       Date:  2020-12-14       Impact factor: 20.543

10.  Assays for measurement of TNF antagonists in practice.

Authors:  Niels Vande Casteele
Journal:  Frontline Gastroenterol       Date:  2016-03-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.